The US Food and Drug Administration (FDA) has approved TriReme Medical's torqueable Glider percutaneous transluminal coronary angioplasty (PTCA) balloon catheter.
Glider PTCA catheter is indicated for treating the stenotic portion of coronary arteries or bypass grafts to improve myocardial perfusion.
Glider utilizes the company’s tip technology and is available in an ultra short balloon length of 4mm designed for focal lesions.
St Vincent Heart Center interventional director James Hermiller said the newly approved ultra short balloon may be useful for focal lesions and side branches.
"Combined with its crossing ability and the stable shaft, I can see it becoming a key tool in these types of cases," Hermiller added.
TriReme Medical president and chief executive officer Eitan Konstantino said in addition to Glider, the company’s portfolio of PTA and PTCA devices include the GliderXtreme, GliderfleX and Chocolate.
"Those products are approved in the US and we are well underway to start getting approvals in our key targeted markets of Japan and China," Konstantino added.